| Product Name |
SARS-CoV-2 Spike Glycoprotein Delta Variant (B.1.617.2, Indian origin) mRNA, with inactivated furin site |
| Description |
This modified mRNA encodes the full-length SARS-CoV-2 spike
glycoprotein B.1.617.2 India origin delta variant, with furin site mutated to PRRD
|
| Features |
- 5' Cap: Capped with ARCA (Anti Reverse Cap Analog,
m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG
(m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
- 5’-UTR: derived from human alpha-globin RNA with an
optimized Kozak sequence
- Codon Optimization: Human
- Mutations: T19R, T95I, G142D, ∆F157+∆R158, E156G, L452R, T478K, D614G, P681R, D950N, P681R, R683A, R685A, D950N
- Nucleotide Modifications: mRNA modified with both
Pseudo-UTP and 5mCTP
- 3’-UTR: comprises two sequence elements derived from the
amino-terminal enhancer of split (AES) mRNA and the mitochondrial
encoded 12S ribosomal RNA to confer RNA stability and high total
protein expression.
- PolyA: 180 nt
|
| Sequence |
Available upon request. |
| Application |
Animal Vaccine Research (Not for human
use) |
| Concentration |
~1 µg/µl |
| Transfection Protocol |
Lipofectamine™
MessengerMAX™ Transfection Reagent Protocol |
| QC |
Agarose gel electrophoresis |
| Shipping |
Dry ice |
| Storage |
-80 oC |
|